UBT251 Injection Phase II Clinical Study (CKD)

This study is testing a new injectable drug called UBT251 in people with chronic kidney disease (CKD) who have significant protein in their urine — a sign of kidney damage. The goal is to see if UBT251 can slow kidney disease progression. **You may be eligible if...** - You are 18–75 years old - You have a BMI of 24 kg/m² or higher - Your kidney filtration rate (eGFR) is between 45 and 90 mL/min/1.73m² - You have had significant protein in your urine (UACR between 300–5000 mg/g) consistently for at least 3 months - If you take blood pressure or kidney-protective medications (like ACE inhibitors, ARBs, or SGLT2 inhibitors), your dose has been stable for at least 4 weeks **You may NOT be eligible if...** - Your kidney function is severely impaired (eGFR below 45) or too high (above 90) - You have had recent changes in your kidney medications - You have other conditions that would make the study drug unsafe Talk to your doctor to see if this trial is right for you.